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Effect of age on lipid profiles in pediatric
heart transplant recipients
OHT is associated with multiple comorbidities,
including hyperlipidemia, which is usually secon-
dary to immunosuppressive agents. CyA and
prednisone have been implicated as the main
contributors to elevated lipid levels (1–5). Hyper-
lipidemia has been shown to play a role in the
development of graft CAV (6–8). Specifically, the
combination of hypercholesterolemia and immu-
nologic injury, to which peri-OHT graft ischemia
and rejection may contribute, leads to extensive,
rapidly progressive atheroarteriosclerosis (6).
Generally, because of the diffuse nature of its
microvascular involvement, CAV cannot be suc-
cessfully treated using percutaneous or surgical
revascularization. Data from both the adult and
pediatric transplant registries found that CAV is
an important cause of death in all OHT patients
and has been linked to 40% of all pediatric deaths
beyond 3 yr post-OHT (9). Therefore, prevention
of CAV by aggressively treating precipitating
factors, such as hyperlipidemia, has become a
primary focus in patient management (8).
While studies have demonstrated that hyperlip-
idemia occurs in pediatric patients after OHT
(10–12), age-related variations have not been
systematically investigated. In the present study,
we hypothesized that hyperlipidemia affects pedi-
atric OHT patients of all ages. Secondarily, we
sought to identify the risk factors for hyperlipide-
mia and to assess the efficacy of hydroxymethyl-
glutaryl-CoA reductase inhibitors (statins).
Patients and methods
Patient sample and data collection
Following institutional review board approval and consent
waiver, lipoprotein profiles of all OHT recipients who
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Abstract: This study’s objectives were to determine if pediatric ortho-
topic heart transplant (OHT) recipients over all ages develop hyper-
lipidemia and, secondarily, to identify the effects of immunosuppressive
agents and statins on lipid profiles in these patients. Retrospective chart
review was performed for pediatric patients transplanted between
January 1987 and June 2002. Of the 100 OHTs performed, 50 patients
satisfied the inclusion criteria and were grouped by age at OHT as
follows: group 1 (n ¼ 16): 0–4 yr; group 2 (n ¼ 10): 5–9 yr; group 3
(n ¼ 15): 10–14 yr; group 4 (n ¼ 9): 15–18 yr. There were 2789 lipid
levels recorded, and each patient had an average of 14 post-
OHT lipoprotein panels measured. Post-OHT total cholesterol and
low-density lipoprotein (LDL) levels were significantly greater than
those of the general population for the entire follow-up period in all age
groups, except for LDL levels in group 2. Cyclosporin level and pred-
nisone dose were positively associated with total cholesterol and LDL
levels (p < 0.03). Statins significantly decreased total cholesterol and
LDL levels (p < 0.001). Hyperlipidemia affects OHT patients of all
ages. Even the youngest patients may benefit from immunosuppression
using an alternative to cyclosporin, such as tacrolimus, and steroid-free
regimens, which may improve lipid profiles. Once safety and efficacy
data are available, all age groups may benefit from statins.
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underwent transplantation at C.S. Mott Children’s Hospital
between January, 1987 and June, 2002 and who survived to
hospital discharge were retrospectively reviewed. Patients
were excluded who were ‡18 yr of age at the time of OHT,
died in the month following OHT, were followed exclusively
at another institution, or were multi-organ transplant
recipients. Each patient’s medical record was reviewed and
all pre- and post-OHT serum lipid levels, including total
cholesterol, HDL, LDL, and triglyceride levels were recor-
ded. Potential risk factors for hyperlipidemia, including
immunosuppressive regimens, CyA levels, treatment for
rejection, BMI, and gender, were also recorded. BMI was
defined as elevated if it was ‡75th percentile for age, com-
pared with healthy historical controls (13). The patients
were grouped by age at OHT as follows: group 1: 0–4 yr,
group 2: 5–9 yr, group 3: 10–14 yr, group 4: 15–18 yr. These
age groups were chosen in order to compare the patients
lipid levels to healthy historical control data published by
the NCEP (14) (Table 1). Of note, these average cholesterol
and LDL levels are similar across all pediatric age groups
and between genders.
Lipoprotein measurements
When available, pre-OHT levels were recorded. Fasting
post-OHT levels were drawn at the time of surveillance
endomyocardial biopsies, which were typically performed
2–4 wk post-OHT, monthly for 3 months, every other
month for 6 months, and every 6–12 months thereafter,
depending on rejection history.
Immunosuppression
Prior to September 1998, the primary immunosuppressive
regimen consisted of CyA, corticosteroids, and AZA.
Thereafter, MMF was used in place of AZA. One patient
was managed with tacrolimus rather than CyA for part of
the follow-up period. CyA was given in a continuous
infusion at 0.5–2 mg/h, beginning immediately postoper-
atively. This was changed to oral dosing of 4–5 mg/kg/
dose twice daily, when a patient was tolerating oral
medications. Doses were adjusted to maintain levels of
200–350 ng/mL during the first post-OHT year and
100–200 ng/mL thereafter, in conjuction with biopsy
scores of £ ISHLT grade 2.
Methylprednisolone (30 mg/kg) i.v. was administered
during reperfusion of the donor organ, followed by 2 mg/
kg/day divided twice daily, starting in the immediate post-
operative period. This was weaned incrementally until a
target maintenance dose of 0.5 mg/kg/day was achieved.
Intravenous corticosteroids were changed to oral predni-
sone as tolerated. The prednisone was weaned further and
occasionally discontinued, depending on the individual
patient rejection histories. For the purposes of this study,
prednisone doses were determined to be low, medium, or
high for three age groups, as shown in Table 2.
Beginning on the second postoperative day, AZA was
initiated at 1 mg/kg/day once daily intravenously or orally.
The dose was increased to a maximum of 2 mg/kg/day and
adjusted to maintain a white blood cell count >4000. After
MMF replaced AZA, patients received oral MMF at a dose
of 1200 mg/m2/day (maximum 3 g). The dose was adjusted
to maintain white blood cell counts >4000 and to minimize
gastrointestinal side effects.
Episodes of ISHLT grade 3A rejection or greater were
treated with a bolus of corticosteroids, either intravenous
methylprednisolone 30 mg/kg/day (maximum 1 g/day) or
oral prednisone 10 mg/kg/day (maximum 100 mg/day) for
three consecutive days. Occasionally, episodes of ISHLT
grade 2 rejection were treated with steroids, depending on
the patient’s rejection history and time from OHT.
Statin use
Post-OHT, a subset of patients were started on either
pravastatin 10 mg once daily or atorvastatin 10 mg once
daily for fasting total cholesterol levels >200 mg/dL. LDL
levels were not used as criteria for starting statins, during the
study period. The statin doses were increased to 20–30 mg
once daily to maintain cholesterol levels <200 mg/dL.
Statistical analysis
Numeric data is expressed as a mean with standard
deviations, unless otherwise specified. Distributions of
lipid levels initially were examined using histograms. Pre-
OHT lipid levels were compared with normal values for
healthy historical control data by one sample t-tests. To
avoid bias of variable timing and number of post-OHT
lipid levels for each patient and to adjust for multiple
potential confounding variables, linear mixed effects
models were used to compare lipid levels for each age
group to normal values and to examine the effects of
immunosuppressive agents, statins, and demographic
characteristics. Lipid levels pre- and post-statin use were
compared using paired t-tests. In order to explore further
the relationship of age and lipid levels, simple linear
regression was performed to compare the highest lipid
levels post-OHT to age at the time of the lipid measure-
ments. Statistical analyses were performed using SAS/
STAT software, version 6 (SAS Institute Inc., Cary, NC,
USA) and the R software, version 1.7.0.
Table 1. Healthy historical control data published by the National Cholesterol
Education Program















Table 2. Prednisone daily doses
Age (yr) Low dose (mg/day) Medium dose (mg/day) High dose (mg/day)
0–4.9 0.25–1.5 1.6–4.9 ‡5.0
5–11.9 0.25–4.9 5.0–14.9 ‡15.0





During the study period, 100 OHTs were per-
formed in 97 patients. Because of the large
number of adult patients and patients who
had follow-up at outside institutions, 50
patients (33 males and 17 females), including
two re-transplants, satisfied the inclusion criteria.
The average patient age at the time of OHT was
8.9 ± 5.5 yr (range 0.2–17.3 yr). Mean follow-
up time was 5.6 ± 4.3 yr (range 0.2–15.5 yr),
and 44% of the patients were followed for
>5 yr. There were 16 patients in group 1
(0–4 yr), six of whom were 12–24 months of
age, 10 in group 2 (5–9 yr), 15 in group 3
(10–14 yr), and nine in group 4 (15–18 yr). The
study population was 76% white, 22% African
American, and 2% Hispanic. Pre-OHT diagno-
ses included congenital heart disease (42%),
dilated cardiomyopathy (34%), hypertrophic
cardiomyopathy (8%), restrictive cardiomyopa-
thy (6%), adriamycin-induced cardiomyopathy
(6%), and vasculopathy of a previous allograft
(4%).
Lipoprotein levels
A total of 2789 lipid levels were recorded. Pre-
OHT total cholesterol and LDL levels were
available for 58 and 36% of the patients,
respectively. In addition to the pre-OHT levels,
each patient had an average of 14 (range 0–41)
lipoprotein panels drawn post-OHT. Group 1
included one patient who was transplanted at
<1 yr of age and was included in the analysis, as
this patient had a pre-OHT profile. This patient’s
post-OHT levels were excluded, however, as it
was unclear that they were drawn in the fasting
state. This was the only patient with no post-
OHT levels.
Lipoprotein levels over time
Total cholesterol
The weighted mean total cholesterol levels for
each group as a function of post-OHT time are
shown in Fig. 1. For comparison, the average for
healthy historical controls (160 mg/dL) and the
treatment threshold chosen by many OHT phy-
sicians (200 mg/dL) are superimposed on the
graph. Levels from patients taking statins were
excluded. Table 3 lists the number of patients in
each group at each time period. The pre-OHT
levels were less than normal values for healthy
historical controls (p < 0.001). Using a linear
mixed effects model, post-OHT levels for all
groups remained significantly above the average
for historical controls (p £ 0.007). For the
majority of the follow-up period, the patients
10–18 yr of age had levels >200 mg/dL, and the
levels remained elevated throughout the follow-
up period. Of the six patients transplanted
between 1 and 2 yr of age, five patients had
post-OHT cholesterol levels >200 mg/dL by the
time they were 3.4 yr of age.
For more than half of the follow-up time,
86% of patients not taking statins (age at OHT
9.3 ± 5.4 yr) had cholesterol levels greater than
the average for healthy children, and 36% (age at
OHT 12.4 ± 3.8 yr) had cholesterol levels
>200 mg/dL. In order to compare the results
to other published studies, 1- and 3-yr post-OHT
levels were assessed for patients not taking
statins. At the 1- and 3-yr follow-up visits,
40 and 34% of these patients, respectively, had
total cholesterol levels >200 mg/dL.
Low-density lipoprotein
The post-OHT weighted mean LDL levels for
each group are shown in Fig. 2. One superim-
posed horizontal line defines the arbitrary treat-


























Fig. 1. Weighted mean total cholesterol levels for each age
group as a function of pre- and post-OHT time. The hori-
zontal lines represent the treatment threshold of 200 mg/dL
and the average for healthy historical controls of 160 mg/
dL. Levels from patients taking statins were excluded from
this graph. Post-OHT levels for all groups remained signi-
ficantly above the average for historical controls
(p £ 0.007).
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physicians in conjunction with total cholesterol
levels >200 mg/dL, and the other marks the
average LDL for healthy children (97 mg/dL).
Levels from patients taking statins were excluded
from this graph. Table 4 shows the number of
patients in each group at each time period. The
pre-OHT LDL levels tended to be lower than
normal values for healthy historical controls
(p ¼ 0.05). Using the linear mixed effects model,
all of the groups, except group 2 (p ¼ 0.3),
remained significantly above the average and
above the treatment threshold throughout fol-
low-up (p £ 0.002). Of the six patients trans-
planted between 1 and 2 yr of age, five patients
had post-OHT LDL levels >100 mg/dL by the
time they were 3.4 yr of age.
For more than half of the follow-up time, 74%
of patients not taking statins (age at OHT
9.3 ± 5.2 yr) had LDL levels greater than aver-
age, and 64% of patients (age at OHT 10.1 ±
4.8 yr) had LDL levels >100 mg/dL. At the
1- and 3-yr follow-up visits, 15 and 14% of
these patients, respectively, had LDL levels
>160 mg/dL.
High-density lipoprotein
The pre-OHT HDL levels were significantly
lower than normal values for healthy historical
controls (p < 0.001). Post-OHT, the average
HDL level was 49 ± 3 mg/dL and not signifi-
cantly different from the average normal value of
54 mg/dL.
Triglycerides
The pre-OHT triglyceride levels were higher than
those of the historical controls (p ¼ 0.04). Simi-
larly, the average post-OHT triglyceride level was
162 ± 24 mg/dL, which was significantly higher
than the average normal value of 62 mg/dL
(p < 0.001).
Effect of rejection, immunosuppressive agents, and statins
Rejection
The 50 patients had a total of 140 episodes of
treated rejection during the study period, and
50% of these episodes occurred in the first post-
OHT year. There was an average of 0.50 episodes
per patient-year of follow-up (group 1: 0.34,
group 2: 0.50, group 3: 0.46, group 4: 1.0). While
maintenance steroid dose was evaluated for its
impact on lipid levels (discussed later in this
section), rejection treatment was not. Because of
the low individual patient rejection frequency,
the usual steroid pulse used for treatment of
rejection should not have had long-term effects
on lipids, and 33% of the rejection episodes were
associated with low CyA levels, which biases the
statistical analysis.
Cyclosporin
As shown in Table 5, adjusting for prednisone
dose, statin use, AZA andMMF use, gender, and
age, CyA level was positively associated with
cholesterol (p < 0.001) and LDL levels
(p < 0.001).
Corticosteroids
Likewise, adjusting for similar factors, predni-























Fig. 2. Weighted mean LDL levels for each age group as a
function of pre- and post-OHT time. The horizontal lines
represent the treatment threshold of 100 mg/dL and the
average LDL for healthy historical controls of 97 mg/dL.
Levels from patients taking statins were excluded from this
graph. Post-OHT levels for all groups, except group 2, were
significantly above the average and above the treatment
threshold (p £ 0.002).
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Table 5. Association of immunosuppressive agents and statins with the
concentration of serum total cholesterol and LDL
Total cholesterol LDL
Change p-value Change p-value
Cyclosporin › <0.001 › <0.001
Prednisone › 0.007 › 0.025
AZA/MMF – 0.948 – 0.708
Statin fl <0.001 fl <0.001
LDL, low density lipoprotein; ›, increase; fl, decrease; –, no change.
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cholesterol (p ¼ 0.007) and LDL levels (p ¼
0.025). The low, medium, and high predni-
sone doses were adjusted for in the statistical
model.
Mycophenolate mofetil and azathioprine
AZA and MMF were not associated with a
significant change in cholesterol or LDL levels
(p > 0.7).
Statins
Sixteen of the 50 study patients were started on
statins at an average age of 16.5 yr (range
6.8–26.1 yr). Using the linear mixed effects
model, statins were associated with a significant
decrease in cholesterol (p < 0.001) and LDL
levels (p < 0.001). Statins decreased total cho-
lesterol by 16% from 211 to 178 mg/dL (p ¼
0.003), but the post-statin levels remained greater
than normal for healthy children (p ¼ 0.02).
Statins also reduced LDL levels by 24% from
128 to 97 mg/dL (p ¼ 0.007), which is the
average value for healthy children.
Effect of age
The effect of age on lipoprotein profiles was
assessed, using the linear mixed effects model.
For this analysis, data collected from patients
while they were taking statins were excluded.
Compared with the other groups, each of the
four age groups had significantly different total
cholesterol (p ¼ 0.024) and LDL curves over
time (p < 0.001). These curves are shown in
Figs 1 and 2. Despite having different curve
patterns, at a fixed time period post-OHT,
there was no significant difference in total
cholesterol (p ¼ 0.2) or in LDL levels between
the four age groups (p ¼ 0.2). In addition, the
highest post-OHT total cholesterol level for
each patient, when he or she was not on
statins, was compared with the age at the time
of the measurement (Fig. 3), and a linear
regression model showed no relationship
between the two (R2 ¼ 0.04, p ¼ 0.2). Similar
analysis for LDL also revealed no relationship
(R2 ¼ 0.02, p ¼ 0.3).
Neither gender (p > 0.2) nor BMI (p > 0.4)
affected total cholesterol, LDL, HDL, or trigly-
ceride levels in the study population.
Discussion
The primary focus of this study was to assess the
effect of age on hyperlipidemia. Obscuring this
effort was the lack of strictly defined levels of
total cholesterol and LDL, which mandate
treatment in this population. By necessity, we
compared the study patients lipid levels to
normal values for healthy historical controls, to
treatment thresholds currently practiced by many
OHT physicians, and to levels defined as hyper-
lipidemia in other studies.
Regardless of the definition, this study dem-
onstrated that hyperlipidemia is common after
pediatric OHT, occurs in all pediatric age
groups, and appears to persist throughout
follow-up. At 1-yr post-OHT, 40% of our
patients had total cholesterol levels >200 mg/
dL, which is similar to 36% reported by Seipelt
et al. (10). At 3 yr post-OHT, 34% of our
patients had levels >200 mg/dL. At 1- and 3-yr
post-OHT, 15 and 14% of patients, respectively,
had LDL levels >160 mg/dL. Similarly,
DiFilippo et al. (12) showed that total choles-
terol and LDL increase by 17% and 20%,
respectively, during the first year post-OHT.
Like the patients in our study, their patients
were immunosuppressed with a CyA-based
regimen. In contrast, Chin et al. (11) found
LDL elevation to be rare after OHT with the
mean LDL levels the same as average values for
healthy historical controls. This difference may
have been because of the differentially small
number of patients and lipid levels included in
their study compared with ours.
In the present study, the pre-OHT total
cholesterol and LDL levels were lower than
average values, and, although the data was
unavailable for review, we suspect this was
because of the severity of the pre-OHT illnesses.
Post-OHT total cholesterol and LDL levels were
significantly above average values for the entire
follow-up period in all age groups, except for
LDL levels in group 2. This may have been
because of significant variation within the levels
of that group. To our knowledge, this report is
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Fig. 3. Relationship of age and highest total cholesterol
level post-OHT for patients not taking statins. R2 ¼ 0.04;
p ¼ 0.2.
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lipoprotein profiles for each patient, numbering
nearly 3000 data points, and to have compared
age-group specific profiles over an average
follow-up period spanning >5 yr. Previous stud-
ies have not reported the effect of age on lipid
profiles. Our study showed that post-OHT
hyperlipidemia occurs independent of age. The
mixed model analysis revealed that, while each
age group had statistically different total choles-
terol curves over time, at any given post-OHT
time point, each age group, even those £ 4 yr of
age, had absolute levels significantly above the
NCEP means.
In addition to investigating the effect of age on
hyperlipidemia, we assessed the various iatro-
genic factors associated with hyperlipidemia in
these patients. In a study examining immuno-
suppressive effects, Becker et al. (1) found pred-
nisone and CyA exposure to be associated with
elevated total cholesterol and LDL levels in adult
heart transplant recipients. Data from our study
corroborated these findings, showing that both
CyA level and prednisone dose were positively
associated with total cholesterol and LDL levels.
Other studies in adults also confirm that predni-
sone and CyA are associated with hyperlipidemia
and that these immunosuppressive agents likely
either increase the production or decrease cata-
bolism of lipoproteins (2–5). OHT patients may
benefit from steroid-free immunosuppressive reg-
imens and/or use of tacrolimus-based immuno-
suppression, which is associated with less
hyperlipidemia compared with CyA (3, 14, 15).
In contrast, our study found no association
between AZA or MMF and hyperlipidemia.
Although this is the first time this association
has been studied in children, Akhlaghi et al. (5)
found no association of AZA use with lipid levels
in adult heart transplant patients.
Furthermore, the present study revealed post-
OHT HDL levels to be similar to normal values.
In contrast, Chin et al. (11) found that post-OHT
HDL levels were abnormally low. They evalu-
ated 28 patients with 71 lipid determinations and
found the HDL to be 43.2 ± 14.7 mg/dL with
the median rank well below the 25th percentile.
Again, this may have been because of the small
sample size in their study. In agreement with our
findings, however, these investigators also
showed that pre- and post-OHT triglyceride
levels were higher than normal values. This is a
potential risk factor for CAV, as demonstrated
by Valantine (16), who found a trend toward
higher triglyceride levels in patients with coron-
ary artery intimal thickening. In her study,
results of 375 simultaneous intravascular ultra-
sound examinations and lipid measurements in
264 OHT recipients were analyzed, and trigly-
ceride measurements at 1- and 2-yr post-OHT
showed a trend toward correlation with maxi-
mum intimal thickness.
As has been shown in multiple studies of adults
and children, we corroborated that statins can be
used effectively in older children to reduce
cholesterol and LDL levels. Total cholesterol
was reduced by 16% and LDL by 24% after the
introduction of a statin. This is similar to a 20%
decline in cholesterol and a 26% decline in LDL
found by Chin et al. (17) in pediatric OHT
patients. It was not the purpose of this study to
fully evaluate the effects of statins; therefore,
efficacy and safety profiles across age groups
were not investigated. In addition, because of the
small sample size, we were unable to investigate
efficacy differences between statins.
Potential clinical implications
The present study confirms that children of all
ages, even those<4 yr of age, who are post-OHT,
particularly those onCyA-based immunosuppres-
sion, should be monitored for hyperlipidemia.
Treatment of hyperlipidemia with a statin should
be considered, as this may not only control the
lipid derangements but also, based on the findings
of other cited studies, may decrease the progres-
sion of associated CAV. In addition to lipid
lowering effects, statins havemultiple antioxidant,
anti-inflammatory, and immunomodulatory
effects, which may enhance vascular endothelial
function, improve vascular health, and slow the
progression of CAV (18–20). Statin safety,
however, has not been established in children
<8–10 yr of age. The safety of atorvastatin,
lovastatin, and simvastatin has been established
for children ‡10 yr of age with familial hyperch-
olesterolemia (21–23), and pravastatin is safe for
these children ‡8 yr of age (24). While one of our
younger patients with elevated total cholesterol
received a statin, our center does not routinely
place children <10 yr of age on statins.
As safety data is lacking, it is not known
whether the risk:benefit ratio would favor the use
of statins in all pediatric OHT age groups (i.e.
those £ 8–10 yr of age) for the treatment of
hypercholesterolemia. Furthermore, safety has
not been established for use of statins in pediatric
patients with normal or only slightly elevated
total cholesterol and LDL levels. This is becom-
ing a more widely discussed issue among pediatric
transplant physicians, as our adult colleagues
now routinely prescribe statins, regardless of lipid
levels, for their coronary protective effects. In
pediatric patients, particularly those who are
Armstrong et al.
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prepubertal, a significant amount of cholesterol is
needed for brain maturation and differentiation,
and depletion of cholesterol in growing tissue
leads to aberrant development (25). Therefore, in
contrast to the new adult practice, caution must
be exercised before statin use is recommended
for all pediatric patients, as subtherapeutic
lipid levels within the more vulnerable age
groups could adversely impact neuro-somatic
development.
Limitations
Although this study included a large number of
patients with many post-OHT lipid levels, it was
limited by the relatively small number of patients
within each age group. Despite this, age was not
found to be associated with lipid levels in further
analyses, which examined the entire study pop-
ulation as one group. Furthermore, secondary
to a lack of adequate therapies for CAV and
to a potentially unfavorable risk:benefit ratio,
coronary angiography was not routinely per-
formed during the study period. The association
of hyperlipidemia with CAV, therefore, could
not be assessed. In addition, as it was not the
purpose of this study to fully evaluate the effects
of statins, efficacy and safety profiles across age
groups were not investigated.
Conclusion
In this study, we report the results of a systematic
analysis evaluating the effects of age on hyper-
lipidemia in pediatric post-OHT patients. We
also investigated the various factors contributing
to hyperlipidemia in these patients and assessed
its reversibility with statin use. Our results
suggest that pediatric OHT patients in all age
groups, even those <4 yr of age, develop
hyperlipidemia and that CyA and prednisone
are positively correlated with increased total
cholesterol and LDL levels. Coupled with their
antioxidant, anti-inflammatory, and immunomo-
dulatory effects, statins may be beneficial to
hyperlipidemic OHT patients of all ages, once
more safety data is available for children <10 yr
of age. In contrast to adult standard practice,
these agents cannot be recommended in children
with normal total cholesterol and LDL levels,
until additional studies demonstrate that they do
not adversely impact neuro-somatic growth.
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